Sorafenib—Drug Delivery Strategies in Primary Liver Cancer

Journal of Functional Biomaterials, Год журнала: 2025, Номер 16(4), С. 148 - 148

Опубликована: Апрель 21, 2025

Current primary liver cancer therapies, including sorafenib and transarterial chemoembolization, face significant limitations due to chemoresistance caused by impaired drug uptake, altered metabolism, other genetic modulations. These challenges contribute relapse rates of 50–80% within five years. The need for improved treatment strategies (adjuvant therapy, unsatisfactory enhanced permeability retention (EPR) effect) has driven research into advanced delivery systems, targeted nanoparticles, biomaterials, combinatory approaches. Therefore, this review evaluates recent advancements in pharmacotherapy, focusing on the potential systems its derivatives. Approaches such as leveraging Kupffer cells tumor migration or utilizing smaller NPs inter-/intracellular delivery, address EPR limitations. Biomaterials therapies targeting have demonstrated effectiveness increasing tumor-specific but clinical evidence remains limited. Combination emerged an interesting solution overcoming broadening therapeutic functionality. Biomimetic employing blood exosomes, provide methods tumors, preventing metastasis, strengthening immune responses. However, differences between preclinical models human physiology remain a barrier translating these findings success. Future must focus development adjuvant therapy refining overcome heterogeneity low accumulation.

Язык: Английский

Nanotechnology-Enhanced siRNA Delivery: Revolutionizing Cancer Therapy

ACS Applied Bio Materials, Год журнала: 2025, Номер unknown

Опубликована: Май 12, 2025

RNA interference (RNAi) has emerged as a transformative approach for cancer therapy, enabling precise gene silencing through small interfering (siRNA). However, the clinical application of siRNA-based treatments faces challenges such rapid degradation, inefficient cellular uptake, and immune system clearance. Nanotechnology-enhanced siRNA delivery revolutionized therapy by addressing these limitations, improving stability, tumor-specific targeting, therapeutic efficacy. Recent advancements in nanocarrier engineering have introduced innovative strategies to enhance safety precision therapies, offering new opportunities personalized medicine. This review highlights three key innovations nanotechnology-enhanced delivery: artificial intelligence (AI)-driven design, multifunctional nanoparticles combined strategies, biomimetic nanocarriers enhanced biocompatibility. AI-driven utilize machine learning algorithms optimize nanoparticle properties, drug release profiles minimizing off-target effects. Multifunctional integrate with chemotherapy, immunotherapy, or photothermal synergistic treatment approaches that outcomes reduce resistance. Biomimetic nanocarriers, including exosome-mimicking systems cell-membrane-coated nanoparticles, improve circulation time, evasion, targeted tumor delivery. These collectively precision, efficiency, therapies. The scope novelty lie their ability overcome primary barriers while paving way clinically viable solutions. provides comprehensive analysis latest developments fabrication, preclinical studies, assessments. By integrating multifunctionality, biomimicry, holds immense potential future therapy.

Язык: Английский